Crinetics Pharmaceuticals, Inc. (CRNX): Price and Financial Metrics

Crinetics Pharmaceuticals, Inc. (CRNX)

Today's Latest Price: $12.08 USD

0.40 (-3.21%)

Updated Oct 30 4:00pm

Add CRNX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CRNX Stock Summary

  • Crinetics Pharmaceuticals Inc's stock had its IPO on July 18, 2018, making it an older stock than only 5.26% of US equities in our set.
  • With a price/sales ratio of 442.85, Crinetics Pharmaceuticals Inc has a higher such ratio than 99% of stocks in our set.
  • Revenue growth over the past 12 months for Crinetics Pharmaceuticals Inc comes in at -47.11%, a number that bests just 4.85% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CRNX, based on their financial statements, market capitalization, and price volatility, are QURE, AUTL, OTIC, RCUS, and SYRS.
  • CRNX's SEC filings can be seen here. And to visit Crinetics Pharmaceuticals Inc's official web site, go to

CRNX Stock Price Chart Interactive Chart >

Price chart for CRNX

CRNX Price/Volume Stats

Current price $12.08 52-week high $26.67
Prev. close $12.48 52-week low $10.63
Day low $11.70 Volume 177,600
Day high $12.58 Avg. volume 142,373
50-day MA $15.14 Dividend yield N/A
200-day MA $16.87 Market Cap 397.24M

Crinetics Pharmaceuticals, Inc. (CRNX) Company Bio

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is based in San Diego, California.

CRNX Latest News Stream

Event/Time News Detail
Loading, please wait...

CRNX Latest Social Stream

Loading social stream, please wait...

View Full CRNX Social Stream

Latest CRNX News From Around the Web

Below are the latest news stories about Crinetics Pharmaceuticals Inc that investors may wish to consider to help them evaluate CRNX as an investment opportunity.

Crinetics Pharma to advance ACTH antagonist candidate into the clinic

Crinetics Pharmaceuticals (CRNX) announces that a presentation of its orally available small molecule adrenocorticotropic hormone ((ACTH)) antagonist was selected for a late-breaking session a the virtual European Congress of Endocrinology on September 8.It is developing the candidate for disorders associated with excess ACTH such as Cushing's disease and congenital adrenal...

Seeking Alpha | September 4, 2020

Crinetics Pharma's paltusotine an Orphan Drug in U.S. for growth hormone disorder

The FDA designates Crinetics Pharmaceuticals' (CRNX) paltusotine an Orphan Drug for the treatment of acromegaly, a disorder in which the pituitary gland secretes too much growth hormone resulting in excessive bone growth, typically in the face, feet and hands.Among the benefits of Orphan Drug status in the U.S. is a...

Seeking Alpha | July 8, 2020

Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly

SAN DIEGO, July 08, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted paltusotine Orphan Drug Designation for the treatment of acromegaly.

Yahoo | July 8, 2020

Should You Avoid Crinetics Pharmaceuticals, Inc. (CRNX)?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 5, 2020

Analysts' Revenue Estimates For Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Are Surging Higher

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) shareholders will have a reason to smile today, with the analysts making...

Yahoo | June 30, 2020

Read More 'CRNX' Stories Here

CRNX Price Returns

1-mo -19.79%
3-mo -12.97%
6-mo -29.02%
1-year -35.02%
3-year N/A
5-year N/A
YTD -51.85%
2019 -16.34%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7685 seconds.